Loading
A phase 2 trial of Visugromab, Nivolumab, Lenvatinib in hepatocellular carcinoma, run by CatalYm GmbH, now recruiting.
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure is a phase 2 interventional study registered as NCT07219459 by CatalYm GmbH, with 104 participants planned, started 2026-03-19 and due to reach its primary completion in 2029-09. Interventions recorded: Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion. Conditions listed: Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound. No results are recorded here; the registry entry is the source.
Shares Visugromab, CatalYm, Nivolumab, Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Nivolumab, Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Lenvatinib, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Advanced hepatocellular carcinoma (BCLC C), Lenvatinib, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Lenvatinib, Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.